Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study
Open Access
- 13 May 2024
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 42 (3) , e3280
Abstract
Hairy cell leukemia (HCL) and HCL‐like disorders have to be distinguished because of their different biology and treatment response. Thus, we conducted a retrospective study on patients with HCL and hairy cell leukemia variant (HCLv) to assess diagnostic algorithms and treatment outcomes in a real‐world setting. We analyzed 225 HCL and 26 HCLv patients with median follow‐up of 67.9 months (HCL) and 20.1 months (HCLv). Median age at diagnosis was 56.2 (HCL) and 69.5 years (HCLv), male predominance was observed in both groups (76.0% vs. 73.1%). Diagnostics was mostly based on morphological evidence of hairy cells in the peripheral blood and bone marrow. At diagnosis, BRAF V600E mutation was detected in 94.7% of examined HCL patients and in no HCLv patient. Front‐line treatment was indicated in 205 (91.1%) HCL and 18 (69.2%) HCLv patients. The majority of HCL patients were administered a cladribine‐based regimen (91.2%). Overall response rate (ORR) was higher in cladribine‐treated patients compared to those given other treatments (97.7% vs. 81.3%), the same applied with achieving Complete remission (CR) (91.2% vs. 62.5%). HCLv treatment was heterogeneous, but cladribine remained the most frequent option (44.4%) with ORR 81.3% and CR rates 43.8%. Second‐line treatment was indicated in 52 HCL and 8 HCLv patients, 25.4% and 44.4% of those treated in first‐line. In the whole HCL group, median time to next treatment (TTNT) was not reached and 10‐year TTNT was estimated at 74.1%. HCLv patients who underwent first‐line treatment had a median TTNT of 56 months. The median overall survival (OS) in HCL patients was not reached compared to HCLv with a median OS of 9.5 years. These data confirm an excellent prognosis for HCL patients treated with cladribine‐based therapy. On the contrary, HCLv with its aggressive behavior represents a group of patients in whom novel treatment approaches are needed.Keywords
This publication has 12 references indexed in Scilit:
- The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory CommitteeBlood, 2022
- Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatmentAmerican Journal of Hematology, 2021
- Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaBlood, 2021
- Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell LeukemiaNew England Journal of Medicine, 2021
- Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General PopulationClinical Lymphoma Myeloma and Leukemia, 2017
- Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- BRAFMutations in Hairy-Cell LeukemiaNew England Journal of Medicine, 2011
- An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosineLeukemia, 2004
- The natural history and clinico-pathological features of the variant form of hairy cell leukemiaLeukemia, 2001
- Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine TreatmentBlood, 1998